Specific expression profile and prognostic significance of peroxiredoxins in grade II-IV astrocytic brain tumors

TamPub

Kuvailutiedot

dc.contributor.author Järvelä, Sally -
dc.contributor.author Rantala, Immo -
dc.contributor.author Rodriguez, Alejandra -
dc.contributor.author Kallio, Heini -
dc.contributor.author Parkkila, Seppo -
dc.contributor.author Kinnula, Vuokko L -
dc.contributor.author Soini, Ylermi -
dc.contributor.author Haapasalo, Hannu -
dc.date.accessioned 2012-06-17T20:16:35Z
dc.date.available 2012-06-15 14:53:49 -
dc.date.available 2012-06-17T20:16:35Z
dc.date.issued 2010 -
dc.identifier.issn 1471-2407 -
dc.identifier.uri http://tampub.uta.fi/handle/10024/66271
dc.description BioMed Central Open access -
dc.description.abstract Background Peroxiredoxins (Prxs) have recently been suggested to have a role in tumorigenesis. Methods We studied the expression of Prx I-VI and their relationship to patient survival in 383 grade II-IV diffuse astrocytic brain tumors. Results Prx I positivity was found in 68%, Prx II in 84%, Prx III in 90%, Prx IV in 5%, Prx V in 4% and Prx VI in 47% of the tumors. Prx I and Prx II expression decreased significantly with increasing malignancy grade (p < 0.001 and p < 0.001). Patients with Prx I or Prx II positive tumors were significantly younger than the average age of all the patients (p = 0.014 and p = 0.005). A lower proliferation rate was associated with Prx I and Prx VI positive tumors (p = 0.019 and p = 0.033), and a lower apoptotic rate was found within Prx I and Prx II positive tumors (p < 0.001 and p = 0.007). Patients with Prx I and Prx II positive tumors had a significantly better survival rate than their Prx-negative counterparts (p = 0.0052 and p = 0.0002). Conclusion The expression of Prx I and Prx II correlates with astrocytic tumor features, such as grade and patient age and proliferation activity (Prx I), and accordingly with patient survival. -
dc.language.iso en -
dc.title Specific expression profile and prognostic significance of peroxiredoxins in grade II-IV astrocytic brain tumors -
dc.type fi=Artikkeli aikakauslehdessä | en=Journal article| -
dc.identifier.urn urn:nbn:uta-3-534 -
dc.identifier.doi 10.1186/1471-2407-10-104 -
dc.type.version fi=Kustantajan versio | en=Publisher's version| -
dc.subject.okm fi=Lääketieteen bioteknologia | en=Medical biotechnology| -
dc.journal.title BMC Cancer -
dc.journal.volume 10 -
dc.journal.number 104 -
dc.journal.volumepagerange 1-10 -
dc.oldstats 60 -

Viite kuuluu kokoelmiin:

Kuvailutiedot